Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Advocacy groups and experts call for decade-long ban on germline editing
18 hours ago
Cell/Gene Tx
Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs
Yesterday
Cytokinetics gets an 'incremental' win for delayed heart drug
Yesterday
TIGIT graveyard expands as GSK drops late-stage asset with iTeos
Yesterday
Vir’s hep B disappointment, Ipsen's new Iqirvo data, plus more from #EASL25
2 days ago
Lilly says further head-to-head trial data back Zepbound over Novo’s Wegovy
2 days ago
Trump says he'll sign order on 'most favored nation' drug price plans Monday
3 days ago
Pharma
Revolution’s KRAS drugs appear competitive in several lung cancer settings
5 days ago
Corvus' early-phase atopic dermatitis data prompt stock rally
5 days ago
'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis
6 days ago
Cell/Gene Tx
In Focus
Lantheus culls late-stage Lilly-partnered prostate cancer radioligand
6 days ago
Gilead reveals plans to put another $11B into US manufacturing
Last week
Pharma
Manufacturing
Theriva’s oncolytic virus succeeds in pancreatic cancer study, but stock falls
Last week
CRISPR Therapeutics' gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%
Last week
Cell/Gene Tx
Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment
Last week
Marea heads to Phase 2b after updated biomarker data show CV drug’s promise
Last week
Vertex pauses study of mRNA therapy for cystic fibrosis
Last week
Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 data
Last week
PTC's Huntington’s study succeeds, but accelerated approval uncertain
Last week
Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact
Last week
Pharma
FDA+
Recursion cuts nearly half of its pipeline, including its most advanced program
Last week
AI
J&J's eye disease gene therapy bota-vec fails in Phase 3 trial
Last week
Cell/Gene Tx
Early bits of in vivo CAR-T human data emerge from biotech trials in China
Last week
China
Cell/Gene Tx
Exclusive: Topas claims success in early test of 'immune tolerance' therapy for celiac disease
Last week
1
2
3
4
Next page
Last page